论文部分内容阅读
目的:观察卡培他滨(CAPE)联合甲酰四氢叶酸钙(LV)和奥沙利铂(OXA)化疗方案(CAPE- LV-OXA)治疗进展期胃癌(AGC)的临床疗效和毒副反应.方法:AGC患者28例接受CAPE-LV-OXA方案治疗,po LV 90 mg/d及CAPE 1250 mg/(m~2.d),d_(1-14);OXA85 mg/m~2,静脉滴注2h,d_1;每3wk为1个疗程.2-6个疗程后观察疗效及其不良反应.结果:可评价疗效25例,完全缓解0例,部分缓解13例,稳定7例,进展5例,有效率(RR)为52%(13/25),中位肿瘤进展时间(TTP)为5.4 (2-13)mo,中位生存时间(MST)为10.3(3-25) mo.毒副反应主要为胃肠道反应、骨髓抑制、手足综合征和黏膜炎等,多为Ⅰ-Ⅱ度毒性反应,所有Ⅲ度毒副反应4例,对症治疗或停止治疗后可缓解.无化疗相关死亡者.结论:CAPE-LV-OXA方案在AGC的治疗中疗效较为肯定,且耐受性良好.
Objective: To observe the curative effect and toxicity of capecitabine (CAPE) combined with leucovorin (LV) and oxaliplatin (OXA) chemotherapy regimen (CAPE-LV-OXA) Response.Methods: 28 patients with AGC were treated with CAPE-LV-OXA regimen, po LV 90 mg / d, CAPE 1250 mg / (m ~ 2.d), d 1-14, OXA 85 mg / Intravenous infusion of 2h, d_1; every 3wk for a course of treatment .2-6 after treatment efficacy and adverse reactions were observed.Results: Evaluation of efficacy in 25 cases, complete remission in 0 cases, partial remission in 13 cases, stable in 7 cases, progress Five patients had an effective rate (RR) of 52% (13/25), a median tumor progression time (TTP) of 5.4 (2-13) mo and a median survival time (MST) of 10.3 (3-25) months. Toxic and side effects mainly gastrointestinal reactions, myelosuppression, hand-foot syndrome and mucositis, mostly Ⅰ-Ⅱ degree toxicity, all Ⅲ degree of toxicity in 4 cases, symptomatic treatment or treatment can be alleviated. Related death.Conclusion: The CAPE-LV-OXA regimen is more effective in the treatment of AGC and is well tolerated.